View in EDS HTML Full Text PDF Full Text

Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.

Saved in:
Bibliographic Details
Title: Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.
Authors: Wang XX; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China., Gao Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China., Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China., Cao JN; Department of Medical Oncology, Fudan University Cancer Center, Shanghai, China., Feng JF; Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, China., Wang HQ; Department of Medical Oncology, People's Hospital of Tianjin, Tianjin, China., Zhang HL; Department of Medical Oncology, Tianjin Cancer Hospital, Tianjin, China., Cai QQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China., Li ZM; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China., Jiang WQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China., Huang HQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. huanghq_sysucc@163.com.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China. huanghq_sysucc@163.com.
Corporate Authors: Lymphoma Committee, Chinese Anti-Cancer Association (CACA)
Source: Annals of hematology [Ann Hematol] 2021 Dec; Vol. 100 (12), pp. 2961-2968. Date of Electronic Publication: 2021 Jul 31.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34331111
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wang+XX%22">Wang XX</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Gao+Y%22">Gao Y</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Jin+J%22">Jin J</searchLink>; Department of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.<br /><searchLink fieldCode="AU" term="%22Cao+JN%22">Cao JN</searchLink>; Department of Medical Oncology, Fudan University Cancer Center, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Feng+JF%22">Feng JF</searchLink>; Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Wang+HQ%22">Wang HQ</searchLink>; Department of Medical Oncology, People's Hospital of Tianjin, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Zhang+HL%22">Zhang HL</searchLink>; Department of Medical Oncology, Tianjin Cancer Hospital, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Cai+QQ%22">Cai QQ</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Li+ZM%22">Li ZM</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Jiang+WQ%22">Jiang WQ</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Huang+HQ%22">Huang HQ</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. huanghq_sysucc@163.com.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China. huanghq_sysucc@163.com.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22Lymphoma+Committee%2C+Chinese+Anti-Cancer+Association+%28CACA%29%22">Lymphoma Committee, Chinese Anti-Cancer Association (CACA)</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229107334%22">Annals of hematology</searchLink> [Ann Hematol] 2021 Dec; Vol. 100 (12), pp. 2961-2968. <i>Date of Electronic Publication: </i>2021 Jul 31.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>9107334 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0584 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209395555%22">09395555 </searchLink><i>NLM ISO Abbreviation: </i>Ann Hematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34331111
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00277-021-04619-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2961
    Titles:
      – TitleFull: Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wang XX
      – PersonEntity:
          Name:
            NameFull: Gao Y
      – PersonEntity:
          Name:
            NameFull: Jin J
      – PersonEntity:
          Name:
            NameFull: Cao JN
      – PersonEntity:
          Name:
            NameFull: Feng JF
      – PersonEntity:
          Name:
            NameFull: Wang HQ
      – PersonEntity:
          Name:
            NameFull: Zhang HL
      – PersonEntity:
          Name:
            NameFull: Cai QQ
      – PersonEntity:
          Name:
            NameFull: Li ZM
      – PersonEntity:
          Name:
            NameFull: Jiang WQ
      – PersonEntity:
          Name:
            NameFull: Huang HQ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2021 Dec
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0584
          Numbering:
            – Type: volume
              Value: 100
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Annals of hematology
              Type: main
ResultId 1